6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome.
about
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.
@en
type
label
6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.
@en
prefLabel
6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.
@en
P2093
P2860
P356
P1476
6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.
@en
P2093
Nicholas M Hickley
Patrick J Chiam
Venkat Kotamarthi
Vivian W Ho
P2860
P304
P356
10.18240/IJO.2016.04.12
P577
2016-04-18T00:00:00Z